Cargando…

Case Report: Coexistence of bullous pemphigoid and psoriasis: Therapeutic challenge and IL17A-targeted parallel treatment strategy

Autoimmune blistering diseases of the skin have all been reported in patients with psoriasis, bullous pemphigoid (BP) being the most frequently observed. The pathophysiologic triggers for BP in psoriatic patients are unclear. Recent observational studies have suggested that chronic psoriatic inflamm...

Descripción completa

Detalles Bibliográficos
Autores principales: Drenovska, Kossara, Valeva, Elia, Shahid, Martin, Vassileva, Snejina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108845/
https://www.ncbi.nlm.nih.gov/pubmed/37077669
http://dx.doi.org/10.3389/fmed.2023.1148660
_version_ 1785026927536373760
author Drenovska, Kossara
Valeva, Elia
Shahid, Martin
Vassileva, Snejina
author_facet Drenovska, Kossara
Valeva, Elia
Shahid, Martin
Vassileva, Snejina
author_sort Drenovska, Kossara
collection PubMed
description Autoimmune blistering diseases of the skin have all been reported in patients with psoriasis, bullous pemphigoid (BP) being the most frequently observed. The pathophysiologic triggers for BP in psoriatic patients are unclear. Recent observational studies have suggested that chronic psoriatic inflammation may cause pathological changes to the basement membrane zone, thus inducing autoimmunity against BP antigens through cross reactivity and “epitope spreading.” The coexistence of BP and psoriasis poses challenging therapeutic dilemmas related to the incompatibility of their standard treatments. Considering the probable common immunologic mechanisms in the pathogenesis of these inflammatory skin disorders, a suitable treatment regimen should be applied for their parallel control. We report three patients, who developed BP in the course of preceding long-lasting psoriasis. Secukinumab was administered as first-line treatment with promising therapeutic effect for both skin disorders and long-term disease control in two of the cases. In the third case, parallel disease control was initially achieved with methotrexate. A few years later, secukinumab was used for the treatment of a relapse of both dermatoses but worsening of BP was observed and methotrexate was reintroduced. Our experience on the therapeutic potential of secukinumab in BP is supported by the data in the literature. Recently, it was demonstrated that the proinflammatory cytokine IL17A has a functional role in the process of skin inflammation in BP, similarly to psoriasis. IL17A inhibition has emerged as a promising therapeutic strategy in patients with extensive or refractory BP but paradoxical development of BP after secukinumab treatment for psoriasis has also been described. This controversy emphasizes the need for further investigation into the development of optimal treatment strategies and recommendations.
format Online
Article
Text
id pubmed-10108845
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101088452023-04-18 Case Report: Coexistence of bullous pemphigoid and psoriasis: Therapeutic challenge and IL17A-targeted parallel treatment strategy Drenovska, Kossara Valeva, Elia Shahid, Martin Vassileva, Snejina Front Med (Lausanne) Medicine Autoimmune blistering diseases of the skin have all been reported in patients with psoriasis, bullous pemphigoid (BP) being the most frequently observed. The pathophysiologic triggers for BP in psoriatic patients are unclear. Recent observational studies have suggested that chronic psoriatic inflammation may cause pathological changes to the basement membrane zone, thus inducing autoimmunity against BP antigens through cross reactivity and “epitope spreading.” The coexistence of BP and psoriasis poses challenging therapeutic dilemmas related to the incompatibility of their standard treatments. Considering the probable common immunologic mechanisms in the pathogenesis of these inflammatory skin disorders, a suitable treatment regimen should be applied for their parallel control. We report three patients, who developed BP in the course of preceding long-lasting psoriasis. Secukinumab was administered as first-line treatment with promising therapeutic effect for both skin disorders and long-term disease control in two of the cases. In the third case, parallel disease control was initially achieved with methotrexate. A few years later, secukinumab was used for the treatment of a relapse of both dermatoses but worsening of BP was observed and methotrexate was reintroduced. Our experience on the therapeutic potential of secukinumab in BP is supported by the data in the literature. Recently, it was demonstrated that the proinflammatory cytokine IL17A has a functional role in the process of skin inflammation in BP, similarly to psoriasis. IL17A inhibition has emerged as a promising therapeutic strategy in patients with extensive or refractory BP but paradoxical development of BP after secukinumab treatment for psoriasis has also been described. This controversy emphasizes the need for further investigation into the development of optimal treatment strategies and recommendations. Frontiers Media S.A. 2023-04-03 /pmc/articles/PMC10108845/ /pubmed/37077669 http://dx.doi.org/10.3389/fmed.2023.1148660 Text en Copyright © 2023 Drenovska, Valeva, Shahid and Vassileva. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Drenovska, Kossara
Valeva, Elia
Shahid, Martin
Vassileva, Snejina
Case Report: Coexistence of bullous pemphigoid and psoriasis: Therapeutic challenge and IL17A-targeted parallel treatment strategy
title Case Report: Coexistence of bullous pemphigoid and psoriasis: Therapeutic challenge and IL17A-targeted parallel treatment strategy
title_full Case Report: Coexistence of bullous pemphigoid and psoriasis: Therapeutic challenge and IL17A-targeted parallel treatment strategy
title_fullStr Case Report: Coexistence of bullous pemphigoid and psoriasis: Therapeutic challenge and IL17A-targeted parallel treatment strategy
title_full_unstemmed Case Report: Coexistence of bullous pemphigoid and psoriasis: Therapeutic challenge and IL17A-targeted parallel treatment strategy
title_short Case Report: Coexistence of bullous pemphigoid and psoriasis: Therapeutic challenge and IL17A-targeted parallel treatment strategy
title_sort case report: coexistence of bullous pemphigoid and psoriasis: therapeutic challenge and il17a-targeted parallel treatment strategy
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108845/
https://www.ncbi.nlm.nih.gov/pubmed/37077669
http://dx.doi.org/10.3389/fmed.2023.1148660
work_keys_str_mv AT drenovskakossara casereportcoexistenceofbullouspemphigoidandpsoriasistherapeuticchallengeandil17atargetedparalleltreatmentstrategy
AT valevaelia casereportcoexistenceofbullouspemphigoidandpsoriasistherapeuticchallengeandil17atargetedparalleltreatmentstrategy
AT shahidmartin casereportcoexistenceofbullouspemphigoidandpsoriasistherapeuticchallengeandil17atargetedparalleltreatmentstrategy
AT vassilevasnejina casereportcoexistenceofbullouspemphigoidandpsoriasistherapeuticchallengeandil17atargetedparalleltreatmentstrategy